With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Amber Tong

When Pliant Therapeutics bagged its $62 million B round almost two years ago, CEO Bernard Coulie positioned its lead program in idiopathic pulmonary fibrosis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Amber Tong

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

Amber Tong

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

With one rival down, Novartis-partnered biotech scores $100M round to fund mid-stage trials of fibrosis drug

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Exclusive: Florida cancer biotech raises $100M Series A